Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 188

1.

Development of a novel digital breath-activated inhaler: Initial particle size characterization and clinical testing.

Kesten S, Israel E, Li G, Mitchell J, Wise R, Stern T.

Pulm Pharmacol Ther. 2018 Dec;53:27-32. doi: 10.1016/j.pupt.2018.08.007. Epub 2018 Sep 7.

2.

Evaluation of pulsed electromagnetic field therapy for the treatment of chronic postoperative pain following lumbar surgery: a pilot, double-blind, randomized, sham-controlled clinical trial.

Sorrell RG, Muhlenfeld J, Moffett J, Stevens G, Kesten S.

J Pain Res. 2018 Jun 22;11:1209-1222. doi: 10.2147/JPR.S164303. eCollection 2018.

3.

Fight, Flight, or Remain Silent? Juggling Multiple Accountabilities throughout the Formative Stage of a Neighborhood Revitalization Initiative.

Kesten SM, Perez DA, Marques DS, Evans SD, Sulma A.

Am J Community Psychol. 2017 Dec;60(3-4):450-458. doi: 10.1002/ajcp.12191. Epub 2017 Nov 20.

PMID:
29154468
4.

Autologous Adipose Derived Regenerative Cells: A Platform for Therapeutic Applications.

Kesten S, Fraser JK.

Surg Technol Int. 2016 Oct 26;29:38-44. Review.

PMID:
27466873
5.

The Athena trials: Autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction.

Henry TD, Pepine CJ, Lambert CR, Traverse JH, Schatz R, Costa M, Povsic TJ, David Anderson R, Willerson JT, Kesten S, Perin EC.

Catheter Cardiovasc Interv. 2017 Feb 1;89(2):169-177. doi: 10.1002/ccd.26601. Epub 2016 Sep 23.

PMID:
27148802
6.

Miami thrives: weaving a poverty reduction coalition.

Evans SD, Rosen AD, Kesten SM, Moore W.

Am J Community Psychol. 2014 Jun;53(3-4):357-68. doi: 10.1007/s10464-014-9657-z.

PMID:
24748284
7.

The localized inflammatory response to bronchoscopic thermal vapor ablation.

Gompelmann D, Eberhardt R, Ernst A, Hopkins P, Egan J, Stanzel F, Valipour A, Wagner M, Witt C, Baker KM, Gotfried MH, Kesten S, Snell G, Herth FJ.

Respiration. 2013;86(4):324-31. doi: 10.1159/000354175. Epub 2013 Aug 23.

8.

Quality and reproducibility of spirometry in COPD patients in a randomized trial (UPLIFT®).

Janssens W, Liu Y, Liu D, Kesten S, Tashkin DP, Celli BR, Decramer M.

Respir Med. 2013 Sep;107(9):1409-16. doi: 10.1016/j.rmed.2013.04.015. Epub 2013 May 25.

9.

Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial.

Cooper CB, Celli BR, Jardim JR, Wise RA, Legg D, Guo J, Kesten S.

Chest. 2013 Aug;144(2):490-497. doi: 10.1378/chest.12-2613.

PMID:
23558890
10.

Evaluation of energy in heated water vapor for the application of lung volume reduction in patients with severe emphysema.

Henne E, Kesten S, Herth FJ.

Respiration. 2013;85(6):493-9. doi: 10.1159/000348273. Epub 2013 Mar 14.

11.

Rationale for the development and the mechanism of action of endoscopic thermal vapor ablation (InterVapor) for the treatment of emphysema.

Kesten S, Anderson JC, Tuck SA.

J Bronchology Interv Pulmonol. 2012 Jul;19(3):237-45. doi: 10.1097/LBR.0b013e31826137bc. Review.

PMID:
23207470
12.

Exacerbation frequency and course of COPD.

Halpin DM, Decramer M, Celli B, Kesten S, Liu D, Tashkin DP.

Int J Chron Obstruct Pulmon Dis. 2012;7:653-61. doi: 10.2147/COPD.S34186. Epub 2012 Sep 21.

13.

Characterization of outcomes 1 year after endoscopic thermal vapor ablation for patients with heterogeneous emphysema.

Herth FJ, Ernst A, Baker KM, Egan JJ, Gotfried MH, Hopkins P, Stanzel F, Valipour A, Wagner M, Witt C, Kesten S, Snell G.

Int J Chron Obstruct Pulmon Dis. 2012;7:397-405. doi: 10.2147/COPD.S31082. Epub 2012 Jul 18.

14.

Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease.

Celli BR, Decramer M, Lystig T, Kesten S, Tashkin DP.

Respir Res. 2012 Aug 6;13:66. doi: 10.1186/1465-9921-13-66.

15.

Effect of combination treatment on lung volumes and exercise endurance time in COPD.

Magnussen H, Paggiaro P, Schmidt H, Kesten S, Metzdorf N, Maltais F.

Respir Med. 2012 Oct;106(10):1413-20. doi: 10.1016/j.rmed.2012.05.011. Epub 2012 Jun 28.

16.

Thermal effect of endoscopic thermal vapour ablation on the lung surface in human ex vivo tissue.

Henne E, Anderson JC, Barry R, Kesten S.

Int J Hyperthermia. 2012;28(5):466-72. doi: 10.3109/02656736.2012.677932. Epub 2012 Jun 12.

17.

Comparison of human lung tissue mass measurements from ex vivo lungs and high resolution CT software analysis.

Henne E, Anderson JC, Lowe N, Kesten S.

BMC Pulm Med. 2012 May 14;12:18. doi: 10.1186/1471-2466-12-18.

18.

Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trial.

Tashkin DP, Celli BR, Decramer M, Lystig T, Liu D, Kesten S.

COPD. 2012 Jun;9(3):289-96. doi: 10.3109/15412555.2012.656211. Epub 2012 Mar 20.

PMID:
22432932
19.

Efficacy of bronchoscopic thermal vapor ablation and lobar fissure completeness in patients with heterogeneous emphysema.

Gompelmann D, Heussel CP, Eberhardt R, Snell G, Hopkins P, Baker K, Witt C, Valipour A, Wagner M, Stanzel F, Egan J, Ernst A, Kesten S, Herth FJ.

Respiration. 2012;83(5):400-6. doi: 10.1159/000336239. Epub 2012 Mar 1.

20.

Cause-specific mortality adjudication in the UPLIFT® COPD trial: findings and recommendations.

McGarvey LP, Magder S, Burkhart D, Kesten S, Liu D, Manuel RC, Niewoehner DE.

Respir Med. 2012 Apr;106(4):515-21. doi: 10.1016/j.rmed.2011.10.009. Epub 2011 Nov 18.

21.

Bronchoscopic thermal vapour ablation therapy in the management of heterogeneous emphysema.

Snell G, Herth FJ, Hopkins P, Baker KM, Witt C, Gotfried MH, Valipour A, Wagner M, Stanzel F, Egan JJ, Kesten S, Ernst A.

Eur Respir J. 2012 Jun;39(6):1326-33. doi: 10.1183/09031936.00092411. Epub 2011 Nov 10.

22.

Adverse health consequences in COPD patients with rapid decline in FEV1--evidence from the UPLIFT trial.

Kesten S, Celli B, Decramer M, Liu D, Tashkin D.

Respir Res. 2011 Sep 28;12:129. doi: 10.1186/1465-9921-12-129.

23.

Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials.

Cooper CB, Anzueto A, Decramer M, Celli B, Tashkin DP, Leimer I, Kesten S.

Int J Chron Obstruct Pulmon Dis. 2011;6:269-75. doi: 10.2147/COPD.S17864. Epub 2011 May 9.

24.

Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT® trial.

Halpin DM, Decramer M, Celli B, Kesten S, Leimer I, Tashkin DP.

Lung. 2011 Aug;189(4):261-8. doi: 10.1007/s00408-011-9301-8. Epub 2011 Jun 16.

25.

Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.

Johnson DS, Stiff C, Lazerwith SE, Kesten SR, Fay LK, Morris M, Beidler D, Liimatta MB, Smith SE, Dudley DT, Sadagopan N, Bhattachar SN, Kesten SJ, Nomanbhoy TK, Cravatt BF, Ahn K.

ACS Med Chem Lett. 2011 Feb 10;2(2):91-96.

26.

Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial.

Fukuchi Y, Fernandez L, Kuo HP, Mahayiddin A, Celli B, Decramer M, Kesten S, Liu D, Tashkin D.

Respirology. 2011 Jul;16(5):825-35. doi: 10.1111/j.1440-1843.2011.01982.x. Erratum in: Respirology. 2011 Nov;16(8):1281.

PMID:
21539680
27.

Premature discontinuation during the UPLIFT study.

Decramer M, Molenberghs G, Liu D, Celli B, Kesten S, Lystig T, Tashkin DP; UPLIFT investigators.

Respir Med. 2011 Oct;105(10):1523-30. doi: 10.1016/j.rmed.2011.04.002. Epub 2011 May 6.

28.

Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial.

Hanania NA, Sharafkhaneh A, Celli B, Decramer M, Lystig T, Kesten S, Tashkin D.

Respir Res. 2011 Jan 11;12:6. doi: 10.1186/1465-9921-12-6.

29.

Development and implementation of treadmill exercise testing protocols in COPD.

Cooper CB, Abrazado M, Legg D, Kesten S.

Int J Chron Obstruct Pulmon Dis. 2010 Oct 12;5:375-85.

30.

COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT).

Morice AH, Celli B, Kesten S, Lystig T, Tashkin D, Decramer M.

Respir Med. 2010 Nov;104(11):1659-67. doi: 10.1016/j.rmed.2010.07.016. Epub 2010 Aug 17.

31.

Effect of obesity on constant workrate exercise in hyperinflated men with COPD.

Laviolette L, Sava F, O'Donnell DE, Webb KA, Hamilton AL, Kesten S, Maltais F.

BMC Pulm Med. 2010 May 30;10:33. doi: 10.1186/1471-2466-10-33.

32.

Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial.

Tashkin D, Celli B, Kesten S, Lystig T, Decramer M.

Respir Med. 2010 Oct;104(10):1495-504. doi: 10.1016/j.rmed.2010.03.033. Epub 2010 Apr 24.

33.

Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial.

Troosters T, Celli B, Lystig T, Kesten S, Mehra S, Tashkin DP, Decramer M; Uplift Investigators.

Eur Respir J. 2010 Jul;36(1):65-73. doi: 10.1183/09031936.00127809. Epub 2010 Feb 25.

34.

Tiotropium HandiHaler in the treatment of COPD: a safety review.

Kesten S, Celli B, Decramer M, Leimer I, Tashkin D.

Int J Chron Obstruct Pulmon Dis. 2009;4:397-409. Epub 2009 Nov 29. Review.

35.

Performance during constant workrate cycling exercise in women with COPD and hyperinflation.

Laviolette L, O'Donnell DE, Webb KA, Hamilton AL, Kesten S, Maltais F.

COPD. 2009 Oct;6(5):340-51.

PMID:
19863363
36.

Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease.

Niewoehner DE, Lapidus R, Cote C, Sharafkhaneh A, Plautz M, Johnson P, Kesten S.

Pulm Pharmacol Ther. 2009 Dec;22(6):587-92. doi: 10.1016/j.pupt.2009.08.006. Epub 2009 Sep 6.

PMID:
19737620
37.

Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease.

Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP; UPLIFT Study Investigators.

Am J Respir Crit Care Med. 2009 Nov 15;180(10):948-55. doi: 10.1164/rccm.200906-0876OC. Epub 2009 Sep 3.

PMID:
19729663
38.

Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial.

Tashkin DP, Celli B, Kesten S, Lystig T, Mehra S, Decramer M.

Eur Respir J. 2010 Feb;35(2):287-94. doi: 10.1183/09031936.00082909. Epub 2009 Aug 28. Erratum in: Eur Respir J. 2010 May;35(5):1195.

39.

Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.

Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP; UPLIFT investigators.

Lancet. 2009 Oct 3;374(9696):1171-8. doi: 10.1016/S0140-6736(09)61298-8. Epub 2009 Aug 27.

PMID:
19716598
40.

Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes.

Anzueto A, Leimer I, Kesten S.

Int J Chron Obstruct Pulmon Dis. 2009;4:245-51. Epub 2009 Jul 20.

41.

Cardiovascular safety of tiotropium in patients with COPD.

Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP.

Chest. 2010 Jan;137(1):20-30. doi: 10.1378/chest.09-0011. Epub 2009 Jul 10.

PMID:
19592475
42.

Evaluation of withdrawal of maintenance tiotropium in COPD.

Adams SG, Anzueto A, Briggs DD Jr, Leimer I, Kesten S.

Respir Med. 2009 Oct;103(10):1415-20. doi: 10.1016/j.rmed.2009.05.018. Epub 2009 Jun 11.

43.

Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations.

Beeh KM, Hederer B, Glaab T, Müller A, Rutten-van Moelken M, Kesten S, Vogelmeier C.

Int J Chron Obstruct Pulmon Dis. 2009;4:119-25. Epub 2009 Apr 15.

44.

Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH).

Johnson DS, Ahn K, Kesten S, Lazerwith SE, Song Y, Morris M, Fay L, Gregory T, Stiff C, Dunbar JB Jr, Liimatta M, Beidler D, Smith S, Nomanbhoy TK, Cravatt BF.

Bioorg Med Chem Lett. 2009 May 15;19(10):2865-9. doi: 10.1016/j.bmcl.2009.03.080. Epub 2009 Mar 24.

45.

Risk of major adverse cardiovascular events with inhaled anticholinergics in patients with chronic obstructive pulmonary disease.

Kesten S, Leimer I, Jara M.

JAMA. 2009 Mar 25;301(12):1224; author reply 1225-6. doi: 10.1001/jama.2008.949. No abstract available.

PMID:
19318648
46.

Reliability of ventilatory parameters during cycle ergometry in multicentre trials in COPD.

O'Donnell DE, Travers J, Webb KA, He Z, Lam YM, Hamilton A, Kesten S, Maltais F, Magnussen H.

Eur Respir J. 2009 Oct;34(4):866-74. doi: 10.1183/09031936.00168708. Epub 2009 Mar 12.

47.

A 4-year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial).

Tashkin D, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M.

Rev Port Pneumol. 2009 Jan-Feb;15(1):137-40. doi: 10.1016/S0873-2159(15)30121-5. English, Portuguese. No abstract available.

48.

A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators.

N Engl J Med. 2008 Oct 9;359(15):1543-54. doi: 10.1056/NEJMoa0805800. Epub 2008 Oct 5.

49.

Responses to tiotropium in African-American and Caucasian patients with chronic obstructive pulmonary disease.

Rice KL, Leimer I, Kesten S, Niewoehner DE.

Transl Res. 2008 Aug;152(2):88-94. doi: 10.1016/j.trsl.2008.05.011. Epub 2008 Jun 23.

PMID:
18674743
50.

Bronchodilator responsiveness in patients with COPD (data from the UPLIFT trial).

Tashkin D, Celli B, Decramer M, Liu D, Burkhart D, Cassino C, Kesten S.

Rev Port Pneumol. 2008 Jul-Aug;14(4):584-7. doi: 10.1016/S0873-2159(15)30267-1. English, Portuguese. No abstract available.

Supplemental Content

Loading ...
Support Center